Inorganic Nanoparticles for Photothermal Therapy

The named startup examples are Sona Nanotech and NanoCarbonTech; FACTS lists 93 companies overall. Sona Nanotech focuses on gold nanorods that generate localized mild heat in tumor models, with a strategy intended to complement immunotherapy. Researchers associated with NanoCarbonTech evaluated Nb₄C₃Tₓ MXene as an NIR-II sensitizer and studied tumor-targeted MXene-antibody conjugates.

Chinese Academy of Sciences CAS leads the listed research organizations with 127 documents in the 24-month window, followed by University of Sichuan with 100 and Southern Medical University with 90. Recent work spans MXene-based materials, photothermal treatment of infected wounds and ReSe₂ nanosheets for ovarian-cancer ablation. These organizations are research leaders in the provided activity data, not necessarily clinical or commercial leaders.

FACTS records $853,542 across 8 grants since 2020 and $768,043,688 across 4 funding rounds. These figures have different categories and should not be combined. The rounds include broad university or project financing entries, so the total is not a reliable measure of capital dedicated specifically to inorganic nanoparticle photothermal therapy.

No single patent holder leads: each of the 8 listed holders has 1 patent in the provided data. They include Case Western Reserve University, Fujian Medical University, IRCCS Ospedale San Raffaele, Alcon and The Regents Of The University Of California. The list also includes Lahjavida LLC, Union Hospital Affiliated to Fujian Medical UniversityFujian and Cha University Industry Academic Cooperation Foundation.

Patent activity is flat in the reported comparison: 12 patents appear in the 24-month window, with 0.0% growth. Publication activity is larger, with 1,967 publications in 2025 and 2.1% growth in the last-year comparison. This points to a research-heavy field, although patent counts alone do not establish commercial readiness or the value of individual inventions.

The field remains predominantly research-stage in the provided data: it records 1,967 publications in 2025, 12 patents in the 24-month window and no clinical trials. Recent in-vivo and preclinical studies explore melanoma, ovarian cancer and localized head-and-neck cancer treatment, but these findings do not establish routine clinical use. The translational challenge includes controlling heating while demonstrating targeting, biodistribution and safety.

In September 2026, researchers reported SERS microneedles with in-situ thermal feedback for infected wounds and studied Nb₄C₃Tₓ MXene for NIR-II melanoma treatment; a separate study reported ReSe₂ nanosheets for ovarian-cancer ablation. These developments address different needs: temperature monitoring, alternative photothermal materials and defined tumor-cell mechanisms. Recent work also explores combinations with drug delivery, gene silencing and immune activation.

FACTS groups the field into plasmonic metal nanostructures, metal chalcogenides, metal oxides, two-dimensional inorganic materials, and rare-earth and semiconductor nanocrystals. Gold nanostructures use plasmonic absorption; copper sulfide represents chalcogenides; MXenes are among the two-dimensional materials. The approaches differ in light absorption, functionalization and potential imaging or catalytic roles, while each presents distinct questions around biological behavior and safety.

Tumor ablation is the largest listed application with 1,838 documents, followed by combination cancer therapy with 1,511 and image-guided treatment with 833. Antimicrobial treatment is also represented, with 698 documents. In practice, researchers use light-generated heat to target tumors or microbial biofilms, and combine it with imaging, drugs or immune approaches; the balance of heat intensity and tissue access depends on the treatment goal.